N⁶-cyclohexylmethyl adenine | 65316-37-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N⁶-cyclohexylmethyl adenine
• 英文别名: N-(Hexahydrobenzyl)adenin；cyclohexylmethyl-(7(9)H-purin-6-yl)-amine；N-(cyclohexylmethyl)-7H-purin-6-amine
• CAS: 65316-37-2
• 化学式: C₁₂H₁₇N₅
• mdl: MFCD12409040
• 分子量: 231.3
• InChiKey: TWNYVXWYJQBLCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.583
• 拓扑面积：
  66.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-氯嘌呤 、 环己甲胺 生成 N⁶-cyclohexylmethyl adenine
  参考文献：
  名称：

  Responses of Phaseolus lunatus callus tissues to cytokinin-active ureidopurines

  摘要：

  DOI：

  10.1016/s0031-9422(00)81566-6

文献信息

• Methods for Altering MRNA Splicing and Treating Familial Dysautonomia and Other Mechanistically Related Disorders
  申请人：Slaugenhaupt Susan A.

  公开号：US20110136836A1

  公开（公告）日：2011-06-09

  This invention relates to methods for altering the splicing of mRNA in cells. In particular, this invention also relates to methods for increasing the ratio of wild type to misspliced forms of mRNA and corresponding encoded proteins in cells possessing a mutant gene encoding either the i) misspliced mRNA corresponding to the mutant protein or ii) a component in the splicing machinery responsible for processing the misspliced mRNA. In addition, this invention relates to treating individuals having a disorder associated with a misspliced mRNA, such as Familial Dysautonomia or Neurofibromatosis 1, by administering to such an individual a cytokinin such as kinetin.

  本发明涉及一种改变细胞中mRNA剪接的方法。特别地，本发明还涉及一种增加野生型mRNA与错剪接形式mRNA及其编码蛋白在携带突变基因编码的细胞中的比例的方法，其中该突变基因编码i) 对应于突变蛋白的错剪接mRNA或ii) 负责处理错剪接mRNA的剪接机制组分。此外，本发明还涉及通过给予细胞素（如激动素）来治疗具有与错剪接mRNA相关的疾病的个体，例如家族性自主神经失调症或神经纤维瘤病1。
• Methods for Altering MRNA Splicing and Treating Familial Dysautonomia by Administering Kinetin, Benzyladenine, and Tocotrienols
  申请人：The General Hospital Corporation

  公开号：US20150111902A1

  公开（公告）日：2015-04-23

  This invention relates to methods for altering the splicing of mRNA in cells. In particular, this invention also relates to methods for increasing the ratio of wild type to misspliced forms of mRNA and corresponding encoded proteins in cells possessing a mutant gene encoding either the i) misspliced mRNA corresponding to the mutant protein or ii) a component in the splicing machinery responsible for processing the misspliced mRNA. In addition, this invention relates to treating individuals having a disorder associated with a misspliced mRNA, such as Familial Dysautonomia or Neurofibromatosis 1, by administering to such an individual a cytokinin such as kinetin.

  本发明涉及改变细胞中mRNA剪接的方法。特别地，本发明还涉及增加野生型与错剪接形式的mRNA及相应编码的蛋白质在携带突变基因编码i)错剪接的mRNA对应的突变蛋白或ii)负责处理错剪接mRNA的剪接机制组分的细胞中的比例的方法。此外，本发明还涉及通过向患有与错剪接mRNA相关的疾病，如家族性自主神经失调症或神经纤维瘤病1的个体，给予细胞分裂素如激动素治疗。
• Methods for altering mRNA splicing and treating familial dysautonomia and other mechanistically related disorders
  申请人：Slaugenhaupt A. Susan

  公开号：US20060014763A1

  公开（公告）日：2006-01-19

  This invention relates to methods for altering the splicing of mRNA in cells. In particular, this invention also relates to methods for increasing the ratio of wild type to misspliced forms of mRNA and corresponding encoded proteins in cells possessing a mutant gene encoding either the i) misspliced mRNA corresponding to the mutant protein or ii) a component in the splicing machinery responsible for processing the misspliced mRNA. In addition, this invention relates to treating individuals having a disorder associated with a misspliced mRNA, such as Familial Dysautonomia or Neurofibromatosis 1, by administering to such an individual a cytokinin such as kinetin.

  本发明涉及改变细胞中 mRNA 剪接的方法。 特别是，本发明还涉及增加细胞中 mRNA 野生型与拼接错误型的比例以及相应的编码蛋白的方法，细胞中的突变基因编码 i) 与突变蛋白相对应的拼接错误 mRNA 或 ii) 负责处理拼接错误 mRNA 的拼接机器中的一个元件。 此外，本发明还涉及通过向患有与错接 mRNA 相关的疾病（如家族性自主神经功能障碍或神经纤维瘤病 1）的人施用细胞分裂素（如激肽）来治疗这些人。
• [EN] METHOD AND COMPOSITION FOR AMELIORATING THE ADVERSE EFFECTS OF AGING
  申请人：SENETEK, PLC

  公开号：WO1992020341A1

  公开（公告）日：1992-11-26

  (EN) 6-(substituted amino)purine cytokinins, including kinetin, have been discovered to ameliorate the adverse effects of aging on mammalian cells, by slowing or reversing the morphological changes that normally accompany aging of such cells, without significantly increasing the growth rate or total proliferative capacity of such cells. Thus, method are provided for countering the adverse effects of aging on cells in culture and in vivo which comprise administering to said cells an adverse-age-effect-ameliorative amount of kinetin or another 6-(substituted amino)purine cytokinin. Compositions for carrying out the methods are also provided. Among the preferred applications of the invention are the preservation of the health of mammalian cells in culture and, by application to human skin of kinetin-containing lotions, ointments or creams, the health and youthful appearance of skin.(FR) On a découvert que des cytokinines de purine (à substitution amino)-6, y compris la kinétine, améliorent les effets fâcheux du vieillissement sur les cellules de mammifères, en ralentissant ou en inversant les modifications morphologiques qui accompagent normalement le vieillissement de ce type de cellules, sans augmenter significativement la vitesse de croissnce ou la capacité de prolifération totale de ces cellules. Cette invention concerne donc des procédés utilisés pour contrecarrer les effets fâcheux du vieillissement sur des cellules cultivées et sur des cellules in vivo, consistant à administrer à ces cellules une quantité améliorant les effets fâcheux du vieillissement, de kinétine ou d'une autre cytokinine de purine (à substitution amino)-6. Des compositions permettant de mettre en application les procédés sont également présentées. Parmi les applications préférées de l'invention, on peut citer la conservation de la santé de cellules de mammifères cultivées et, l'aspect sain et jeune de la peau lorsqu'on applique sur la peau d'une personne des lotions, des onguents ou des crèmes contenant de la kinétine.

  6-（取代氨基）嘌呤细胞因子（包括亲脂素）已被发现能够改善哺乳动物细胞衰老的不利影响，通过减缓或逆转通常伴随细胞衰老的形态变化，而不会显著增加细胞的生长速率或总增殖能力。因此，为应对细胞在培养和体内的衰老不利影响提供了方法，具体包括向细胞中输注缓解衰老不利影响的亲脂素或另一类6-（取代氨基）嘌呤细胞因子的去不利作用量的数量。还提供了执行上述方法的成分。 preferred发明的应用包括维护哺乳动物细胞的健康（在细胞培养中），以及通过亲脂素包含的乳液、药膏或霜来维护皮肤的健康和青春状态。
• Synthesis and Biological Activity of Some 6-(Substituted)-aminopurines
  作者：Charles G. Skinner、Pete D. Gardner、William Shive

  DOI：10.1021/ja01568a048

  日期：1957.6